Technology
Health
Biotechnology

Cytori Therapeutics

$0.2787
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0008 (-0.29%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CYTX and other stocks, options, ETFs, and crypto commission-free!

About

Cytori Therapeutics Inc. Common Stock, also called Cytori Therapeutics, is a late stage cell therapy company which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. Read More It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.

Employees
37
Headquarters
San Diego, California
Founded
1996
Market Cap
3.27M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
440.54K
High Today
$0.29
Low Today
$0.265
Open Price
$0.2795
Volume
593.10K
52 Week High
$3.30
52 Week Low
$0.215

Collections

Technology
Health
Biotechnology
Therapy
Medical
US
North America

News

Associated PressMar 7

Cytori Files Pre-submission Request for New Drug Application

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that it officially filed a formal new drug application pre-submission request to the European Medicine Agency (EMA) for Dox...

826
MarketBeatMar 7

Stock Price, News, & Analysis for Cytori Therapeutics

Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company's second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has complet...

108

Earnings

-$0.59
-$0.41
-$0.24
-$0.06
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.30 per share
Actual
Expected Mar 27, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.